| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/03/2002 | US20020002154 Method and composition for treatment of inflammatory conditions |
| 01/03/2002 | US20020002151 Minocycline-containing compositions |
| 01/03/2002 | US20020002148 Antibacterial aqueous ophthalmic formulations containing ofloxacin and use of chitosan for solubilizing ofloxacin suspended in an aqueous media |
| 01/03/2002 | US20020002147 Stabilizing amount of magnesium stearate; extended dosage formed by extrusion and spheronization and coated with a seal coating; nucleoside reverse transcriptase inhibitor; treatment of retroviruses, HIV |
| 01/03/2002 | US20020002141 For inhibiting apoptosis or apoptosis-like cell death |
| 01/03/2002 | US20020002133 Stabilized granulocyte colony stimulating factor |
| 01/03/2002 | US20020001667 Apparatus and method for coating a material |
| 01/03/2002 | US20020001631 Human growth hormone |
| 01/03/2002 | US20020001629 Pretreatment; inducing stress response |
| 01/03/2002 | US20020001622 By blending redried corn starch, silica and at least one vitamin in a blender in any order to make a dry, free-flowing powder; economical method |
| 01/03/2002 | US20020001621 By using a variety of polymers, having varying starting molecular weights, by varying the hold time of the nucleophilic compound/polymer solution; encapsulated active agents |
| 01/03/2002 | US20020001620 Prepared by mixing and disaggregating of the carbon nanotubes; use in medicine or dentistry as a bone cement, dental restoration or prosthesis |
| 01/03/2002 | US20020001619 Hydrophilic polymer, biologically active agent, and at least one precipitating agent, where biologically active agent is co-precipitated within the hydrophilic polymer |
| 01/03/2002 | US20020001617 Mixing a spray-dried particulate containing an active ingredient, a sublimable substance, a polyethylene glycol, and additive, tableting, and drying to sublime the sublimable substance until tablet becomes porous |
| 01/03/2002 | US20020001616 Novel method of treatment |
| 01/03/2002 | US20020001614 Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof |
| 01/03/2002 | US20020001613 Shear mixing of hydrophobic liquid phase and hydrophilic liquid phase using cavitational forces to rapidly hydrate the hydrophobic phase with the hydrophilic phase; said force is created by a member that vibrates at an ultrasonic frequency |
| 01/03/2002 | US20020001612 Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| 01/03/2002 | US20020001611 The latter for stability in aqueous medium, for human consumption |
| 01/03/2002 | US20020001610 Active ingredient delivery systems and devices based on porous matrices |
| 01/03/2002 | US20020001608 Biodegradable implant precursor |
| 01/03/2002 | US20020001607 Perfluoroalkane or fluorohydrocarbons deoxygenated which prevents their damage to the retina or intraocular structures; use such as treating ischemic retinal disorders |
| 01/03/2002 | US20020001605 Washing composition |
| 01/03/2002 | US20020001601 Remains stable packaged in flexible tube; microbiocides; fungicides |
| 01/03/2002 | US20020001600 Method of using lectins for prevention and treatment of skin diseases and disorders |
| 01/03/2002 | US20020001599 Heating, controlling temperature, homogeneity mixture |
| 01/03/2002 | US20020001598 Pharmaceutical microspheres containing valproic acid for oral administration |
| 01/03/2002 | US20020001591 Compositions for the delivery of antigens |
| 01/03/2002 | US20020001571 A composite polymer system comprising a stimuli-responsive polymer selected from R-acrylamide, R1-acryalate, R2-acrylic acid, polyethylene glycol(R,R1,R2=H or alkyl) at least one second polymer such as, polysaccharide, cellulose, polyester |
| 01/03/2002 | US20020001567 Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| 01/03/2002 | US20020001332 Mounting arrangement for auxiliary burner or lance |
| 01/03/2002 | US20020000681 Method of forming nanoparticles and microparticles of controllable size using supercritical fluids and ultrasound |
| 01/03/2002 | US20020000225 Lockout mechanism for aerosol drug delivery devices |
| 01/03/2002 | US20020000176 Non-gelatin solution of hydroxypropylmethylcellulose and alcohol with second solution of gelling gum and hydrolyzing agent |
| 01/03/2002 | DE10126393A1 Medikamentenpumpe mit Verstärkungsrillen Drug pump with reinforcing grooves |
| 01/03/2002 | DE10031044A1 Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere Endoparasiticides means of voluntary oral ingestion by animals |
| 01/03/2002 | DE10029646A1 Trägerfolie für selbsthaftende Laminate mit reduzierter Auflagefläche Base film for self-adhesive laminates with reduced contact surface |
| 01/03/2002 | DE10029462A1 New water soluble polymers based on macromonomer with polyalkylene oxide units, useful as adjuvants in cosmetic, pharmaceutical and agrochemical compositions |
| 01/03/2002 | DE10029404A1 Colloidal cyclosporin formulation for treatment and prevention of skin and mucous membrane disorders contains cyclosporin, lipophilic phase, mixture of surfactant and cosurfactant and hydrophilic phase |
| 01/03/2002 | CA2415836A1 Confectionery product containing active ingredients |
| 01/03/2002 | CA2415236A1 Novispirins: antimicrobial peptides |
| 01/03/2002 | CA2414389A1 Methods of treating neutrophil-related diseases with topical anesthetics |
| 01/03/2002 | CA2413816A1 Controlled release arginine formulations |
| 01/03/2002 | CA2413545A1 Methods and compositions for treating pain of the mucous membrane |
| 01/03/2002 | CA2413330A1 Wet milling process |
| 01/03/2002 | CA2413157A1 Biodegradable vehicles and delivery systems of biologically active substances |
| 01/03/2002 | CA2413143A1 A synthetic bulk laxative |
| 01/03/2002 | CA2412490A1 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| 01/03/2002 | CA2412024A1 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| 01/03/2002 | CA2412017A1 Multiple stimulus reversible hydrogels |
| 01/03/2002 | CA2411055A1 Structures and compositions increasing the stability of peroxide actives |
| 01/02/2002 | WO2002098412A1 Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester |
| 01/02/2002 | WO2002096394A2 Pharmaceutical composition containing stool softener such as polaxamer and enteric coated particles of bisacodyl |
| 01/02/2002 | EP1167433A1 Product based on polysaccharides coprocessed with an insoluble disintegrant, process for its preparation and the use |
| 01/02/2002 | EP1167379A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167378A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167377A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1166811A2 Metered dose inhaler for fluticasone propionate |
| 01/02/2002 | EP1166801A1 Preparations containing silicon dioxide to improve the taste thereof |
| 01/02/2002 | EP1166800A1 Pharmaceutical compositions containing antibiotics and fructan mixtures |
| 01/02/2002 | EP1166794A2 Method of treating retained pulmonary secretions |
| 01/02/2002 | EP1166777A1 Taste masked pharmaceutical particles |
| 01/02/2002 | EP1166776A2 Process of preparation of solid oral dosage forms with delayed release |
| 01/02/2002 | EP1166775A2 Targeted liposome gene delivery |
| 01/02/2002 | EP1166774A1 Pharmaceutical aerosol compositions comprising a flavouring oil |
| 01/02/2002 | EP1166773A1 Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof |
| 01/02/2002 | EP1166771A1 Invers autoinversible latices based on fatty acid esters and cosmetic, dermocosmetic, dermopharmaceutic or pharmaceutic compositions |
| 01/02/2002 | EP1166769A1 Lipid composition containing a liquid crystal structure |
| 01/02/2002 | EP1166653A2 Iron-containing protein composition |
| 01/02/2002 | EP1166651A1 Synthetic sweetener |
| 01/02/2002 | EP1165716A1 Adhesives |
| 01/02/2002 | EP1165620A1 INCLUSION COMPLEXES OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES WITH $g(g)-CYCLODEXTRIN |
| 01/02/2002 | EP1165614A1 Antibodies against phosphomannan that are protective against candidiasis |
| 01/02/2002 | EP1165612A2 A method for purifying human growth hormone |
| 01/02/2002 | EP1165611A1 Retro-inverso prosaposin-derived peptides and use thereof |
| 01/02/2002 | EP1165558A1 Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| 01/02/2002 | EP1165490A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 01/02/2002 | EP1165487A1 Derivatives of venlafaxine and methods of preparing and using the same |
| 01/02/2002 | EP1165197A1 Crystallization process for producing fine crystal products |
| 01/02/2002 | EP1165183A1 Low dose estrogen interrupted hormone replacement therapy |
| 01/02/2002 | EP1165142A2 Lipid-based artificial particles inducing cell-mediated immunity |
| 01/02/2002 | EP1165141A2 Novel formulations comprising lipid-regulating agents |
| 01/02/2002 | EP1165140A2 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| 01/02/2002 | EP1165132A2 Dry formulation for transcutaneous immunization |
| 01/02/2002 | EP1165126A1 Human papillomavirus vaccine with disassembled and reassembled virus-like particles |
| 01/02/2002 | EP1165120A2 A uro-genital condition treatment system |
| 01/02/2002 | EP1165112A1 Modulators of polysaccharides and uses thereof |
| 01/02/2002 | EP1165106A2 Composition and method for inducing apoptosis in prostate cancer cells |
| 01/02/2002 | EP1165101A2 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs) |
| 01/02/2002 | EP1165097A2 A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| 01/02/2002 | EP1165094A1 Dispersible macrolide compounds and method for the production thereof |
| 01/02/2002 | EP1165091A1 Pharmaceutical emulsions for retroviral protease inhibitors |
| 01/02/2002 | EP1165083A2 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| 01/02/2002 | EP1165081A1 Tolperison-containing, pharmaceutical preparation for oral administration |
| 01/02/2002 | EP1165077A2 Viral treatment |
| 01/02/2002 | EP1165074A2 Viral treatment |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165070A1 Thiadiazolyl urea or thiourea derivatitives for antiviral treatment |
| 01/02/2002 | EP1165065A1 Swallowable tablets with high content of n-acetylcysteine |
| 01/02/2002 | EP1165058A2 Use of azalide antibiotics for the topical treatment or prevention of ocular infections |